Post-COVID sequelae effect in chronic fatigue syndrome: SARS-CoV-2 triggers latent adenovirus in the oral mucosa.
Hannestad, Ulf, Apostolou, Eirini, Sjögren, Per et al. · Frontiers in medicine · 2023 · DOI
Quick Summary
This study found that people with ME/CFS who caught COVID-19 showed signs of a dormant virus (adenovirus) waking up in their mouth and throat. The researchers compared saliva samples from ME/CFS patients and healthy people, and only the ME/CFS patients showed this reactivation after COVID-19 infection. This suggests that ME/CFS patients may have a weakened immune system that cannot keep these latent viruses under control when faced with a new infection like COVID-19.
Why It Matters
Understanding viral reactivation patterns in ME/CFS may explain why some patients experience symptom exacerbation following acute infections like COVID-19. These findings could identify a subgroup of ME/CFS patients who might benefit from antiviral therapies targeting adenovirus or immune-modulating treatments. This research provides molecular evidence supporting the immune dysfunction hypothesis in ME/CFS and highlights post-COVID infection as a potential trigger for disease progression.
Observed Findings
Significantly elevated anti-HAdV IgG antibodies in saliva were found exclusively in ME/CFS patients after SARS-CoV-2 infection, not in healthy controls.
Longitudinal analysis in the same individuals confirmed HAdV IgG elevation occurred after COVID-19 infection.
No corresponding anti-HAdV IgG elevation was detected in plasma samples, suggesting oral mucosa-specific reactivation.
The adenovirus reactivation pattern was not observed in the healthy control group despite similar SARS-CoV-2 exposure.
Inferred Conclusions
SARS-CoV-2 infection triggers reactivation of dormant adenovirus specifically in ME/CFS patients' oral mucosa.
ME/CFS patients have exhausted or dysfunctional antiviral immune responses that cannot contain latent viruses under infectious stress.
Adenovirus reactivation may be a marker of impaired immune control in ME/CFS and could represent a therapeutic target.
Remaining Questions
Does adenovirus reactivation directly contribute to symptom severity in post-COVID ME/CFS, or is it merely an indicator of immune dysfunction?
What specific immune abnormalities in ME/CFS allow adenovirus reactivation, and can these be therapeutically corrected?
Would antiviral therapy targeting adenovirus improve clinical outcomes in ME/CFS patients with documented reactivation?
What This Study Does Not Prove
This study does not prove that adenovirus reactivation causes ME/CFS symptoms or that treating adenovirus will improve ME/CFS outcomes. The research demonstrates correlation and reactivation patterns but does not establish causation or whether the detected antibodies reflect active viral replication. The findings apply specifically to the oral mucosa and may not generalize to systemic pathology or all ME/CFS patient populations.